Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease

BACKGROUND: Knowledge of possible cardiovascular risks from Parkinson's disease (PD) medications is critical to informing safe and effective treatment decisions. The objective of our study was to determine whether PD patients treated with nonergot dopamine agonists (DAs) are at increased risk o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mov Disord Clin Pract
Autors principals: Crispo, James A.G., Willis, Allison W., Thibault, Dylan P., Fortin, Yannick, Emons, Matthew, Bjerre, Lise M., Kohen, Dafna E., Perez‐Lloret, Santiago, Mattison, Donald, Krewski, Daniel
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6178630/
https://ncbi.nlm.nih.gov/pubmed/30363519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12286
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars